182 related articles for article (PubMed ID: 26861777)
1. New effective chemically synthesized anti-smallpox compound NIOCH-14.
Mazurkov OY; Kabanov AS; Shishkina LN; Sergeev AA; Skarnovich MO; Bormotov NI; Skarnovich MA; Ovchinnikova AS; Titova KA; Galahova DO; Bulychev LE; Sergeev AA; Taranov OS; Selivanov BA; Tikhonov AY; Zavjalov EL; Agafonov AP; Sergeev AN
J Gen Virol; 2016 May; 97(5):1229-1239. PubMed ID: 26861777
[TBL] [Abstract][Full Text] [Related]
2. [A comparative study of the antiviral activity of chemical compounds concerning the orthopoxviruses experiments in vivo].
Kabanov AS; Sergeev AA; Shishkina LN; Bulychev LE; Skarnovich MO; Sergeev AA; Bormotov NI; P'iankov OV; Serova OA; Bodnev SA; Selivanov BA; Tikhonov AIa; Agafonov AP; Sergeev AN
Vopr Virusol; 2013; 58(4):39-43. PubMed ID: 24354064
[TBL] [Abstract][Full Text] [Related]
3. Estimation of Absolute Bioavailability of the Chemical Substance of the Anti-Smallpox Preparation NIOCH-14 in Mice.
Mazurkov OY; Shishkina LN; Bormotov NI; Skarnovich MO; Serova OA; Mazurkova NA; Chernonosov AA; Tikhonov AY; Selivanov BA
Bull Exp Biol Med; 2020 Dec; 170(2):207-210. PubMed ID: 33263846
[TBL] [Abstract][Full Text] [Related]
4. [THE USE OF THE MODEL MOUSE ICR--VARIOLA VIRUS FOR EVALUATION OF ANTIVIRAL DRUG EFFICACY].
Titova KA; Sergeev AA; Kabanov AS; Bulychev LE; Sergeev AA; Galakhova DO; Shishkina LN; Zamedyanskaya AS; Nesterov AE; Glotov AG; Taranov OS; Omigov VV; Agafonov AP; Sergeev AN
Vopr Virusol; 2016; 61(2):79-84. PubMed ID: 27451500
[TBL] [Abstract][Full Text] [Related]
5. In vitro efficacy of ST246 against smallpox and monkeypox.
Smith SK; Olson VA; Karem KL; Jordan R; Hruby DE; Damon IK
Antimicrob Agents Chemother; 2009 Mar; 53(3):1007-12. PubMed ID: 19075062
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Efficacy of a Potential Smallpox Therapeutic, Brincidofovir, in a Lethal Monkeypox Virus Animal Model.
Hutson CL; Kondas AV; Mauldin MR; Doty JB; Grossi IM; Morgan CN; Ostergaard SD; Hughes CM; Nakazawa Y; Kling C; Martin BE; Ellison JA; Carroll DS; Gallardo-Romero NF; Olson VA
mSphere; 2021 Feb; 6(1):. PubMed ID: 33536322
[TBL] [Abstract][Full Text] [Related]
7. Using ICR and SCID mice as animal models for smallpox to assess antiviral drug efficacy.
Titova KA; Sergeev AA; Zamedyanskaya AS; Galahova DO; Kabanov AS; Morozova AA; Bulychev LE; Sergeev AA; Glotova TI; Shishkina LN; Taranov OS; Omigov VV; Zavjalov EL; Agafonov AP; Sergeev AN
J Gen Virol; 2015 Sep; 96(9):2832-2843. PubMed ID: 26067292
[TBL] [Abstract][Full Text] [Related]
8. Safety and Pharmacokinetics of the Substance of the Anti-Smallpox Drug NIOCH-14 after Oral Administration to Laboratory Animals.
Shishkina LN; Mazurkov OY; Bormotov NI; Skarnovich MO; Serova OA; Mazurkova NA; Skarnovich MA; Chernonosov AA; Selivanov BA; Tikhonov AY; Gamaley SG; Shimina GG; Sysoyeva GM; Taranov OS; Danilenko ED; Agafonov AP; Maksyutov RA
Viruses; 2023 Jan; 15(1):. PubMed ID: 36680245
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic modeling to determine the dose of ST-246 to protect against smallpox in humans.
Leeds JM; Fenneteau F; Gosselin NH; Mouksassi MS; Kassir N; Marier JF; Chen Y; Grosenbach D; Frimm AE; Honeychurch KM; Chinsangaram J; Tyavanagimatt SR; Hruby DE; Jordan R
Antimicrob Agents Chemother; 2013 Mar; 57(3):1136-43. PubMed ID: 23254433
[TBL] [Abstract][Full Text] [Related]
10. New Perspectives on Antimicrobial Agents: Tecovirimat for Treatment of Human Monkeypox Virus.
DeLaurentis CE; Kiser J; Zucker J
Antimicrob Agents Chemother; 2022 Dec; 66(12):e0122622. PubMed ID: 36374026
[TBL] [Abstract][Full Text] [Related]
11. Using the Ground Squirrel (Marmota bobak) as an Animal Model to Assess Monkeypox Drug Efficacy.
Sergeev AA; Kabanov AS; Bulychev LE; Sergeev AA; Pyankov OV; Bodnev SA; Galahova DO; Zamedyanskaya AS; Titova KA; Glotova TI; Taranov OS; Omigov VV; Shishkina LN; Agafonov AP; Sergeev AN
Transbound Emerg Dis; 2017 Feb; 64(1):226-236. PubMed ID: 25944444
[TBL] [Abstract][Full Text] [Related]
12. Treatment with the smallpox antiviral tecovirimat (ST-246) alone or in combination with ACAM2000 vaccination is effective as a postsymptomatic therapy for monkeypox virus infection.
Berhanu A; Prigge JT; Silvera PM; Honeychurch KM; Hruby DE; Grosenbach DW
Antimicrob Agents Chemother; 2015 Jul; 59(7):4296-300. PubMed ID: 25896687
[TBL] [Abstract][Full Text] [Related]
13. The Possibility of Using the ICR Mouse as an Animal Model to Assess Antimonkeypox Drug Efficacy.
Sergeev AA; Kabanov AS; Bulychev LE; Sergeev AA; Pyankov OV; Bodnev SA; Galahova DO; Zamedyanskaya AS; Titova KA; Glotov AG; Taranov OS; Omigov VV; Shishkina LN; Agafonov AP; Sergeev AN
Transbound Emerg Dis; 2016 Oct; 63(5):e419-30. PubMed ID: 25597343
[TBL] [Abstract][Full Text] [Related]
14. ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestation.
Berhanu A; King DS; Mosier S; Jordan R; Jones KF; Hruby DE; Grosenbach DW
Antimicrob Agents Chemother; 2009 Dec; 53(12):4999-5009. PubMed ID: 19752270
[TBL] [Abstract][Full Text] [Related]
15. A human recombinant analogue to plasma-derived vaccinia immunoglobulin prophylactically and therapeutically protects against lethal orthopoxvirus challenge.
Parker S; D'Angelo J; Buller RM; Smee DF; Lantto J; Nielsen H; Jensen A; Prichard M; George SL
Antiviral Res; 2021 Nov; 195():105179. PubMed ID: 34530009
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox - an animal model of smallpox.
Parker S; Chen NG; Foster S; Hartzler H; Hembrador E; Hruby D; Jordan R; Lanier R; Painter G; Painter W; Sagartz JE; Schriewer J; Mark Buller R
Antiviral Res; 2012 Apr; 94(1):44-53. PubMed ID: 22381921
[TBL] [Abstract][Full Text] [Related]
17. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge.
Yang G; Pevear DC; Davies MH; Collett MS; Bailey T; Rippen S; Barone L; Burns C; Rhodes G; Tohan S; Huggins JW; Baker RO; Buller RL; Touchette E; Waller K; Schriewer J; Neyts J; DeClercq E; Jones K; Hruby D; Jordan R
J Virol; 2005 Oct; 79(20):13139-49. PubMed ID: 16189015
[TBL] [Abstract][Full Text] [Related]
18. ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
Jordan R; Goff A; Frimm A; Corrado ML; Hensley LE; Byrd CM; Mucker E; Shamblin J; Bolken TC; Wlazlowski C; Johnson W; Chapman J; Twenhafel N; Tyavanagimatt S; Amantana A; Chinsangaram J; Hruby DE; Huggins J
Antimicrob Agents Chemother; 2009 May; 53(5):1817-22. PubMed ID: 19223621
[TBL] [Abstract][Full Text] [Related]
19. Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection.
Stittelaar KJ; Neyts J; Naesens L; van Amerongen G; van Lavieren RF; Holý A; De Clercq E; Niesters HG; Fries E; Maas C; Mulder PG; van der Zeijst BA; Osterhaus AD
Nature; 2006 Feb; 439(7077):745-8. PubMed ID: 16341204
[TBL] [Abstract][Full Text] [Related]
20. A mouse model of lethal infection for evaluating prophylactics and therapeutics against Monkeypox virus.
Stabenow J; Buller RM; Schriewer J; West C; Sagartz JE; Parker S
J Virol; 2010 Apr; 84(8):3909-20. PubMed ID: 20130052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
